Key result
Echocardiographic screening according to COG guidelines versus no screening yielded an ICER of $61,500 per QALY, extending QALYs by 1.6 months and reducing heart failure incidence by 18% at 30 years.
Why the study?
Is echocardiographic screening according to COG guidelines cost-effective for preventing heart failure in childhood cancer survivors treated with anthracyclines?
Is echocardiographic screening according to COG guidelines cost-effective for preventing heart failure in childhood cancer survivors treated with anthracyclines?
Effect estimate: ICER $61,500
Echocardiographic screening according to COG guidelines is cost-effective (<$100,000/QALY) for reducing heart failure risk in childhood cancer survivors, though less frequent screening may offer similar benefits at lower cost.
No takes yet. Share an insight, caveat, or question.
Supports modeled COG screening as cost-effective for anthracycline survivors; leaves open prospective validation of frequency and outcomes.
Wong et al. (2014) studied Childhood cancer survivors at risk for treatment-related heart failure. Echocardiographic screening (COG guidelines) vs. No screening was evaluated on Quality-adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs), and cumulative incidence of heart failure (ICER $61,500). Echocardiographic screening according to COG guidelines versus no screening yielded an ICER of $61,500 per QALY, extending QALYs by 1.6 months and reducing heart failure incidence by 18% at 30 years.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: